RE: Half year Report21 Sep 2022 17:12
Dactions
I personally don’t share the same opinion and see it differently. I see the revenue tripled and and we now turned a profit of 1m from a loss of £269,000. New products in blood testing to come and delivered on current products. We all know they are building a brand for when Covid related products fall however this is continuing whilst they reinvent in the development of new products.
MHC is debt free so now interest payments rising like many other indebted companies and a clear froth strategy. This market in every sector is challenging with current macro economic conditions and I see these results as MHC demonstrating they intend to grow organically and with other lines of sales. The lack of share payment in my view is another way to show how prudent they have been in setting targets and not just giving shares away freely which dilutes the value.
I’m frustrated but not overly disappointed but will await tomorrow’s meeting and scrutinise what is said.
I do agree and also expected that the share price should be at least 3.5p however the markets are totally depressed but that’s the time to buy in my opinion